Mergers & Acquisitions - Biotechnology


Current filters:


Popular Filters

76 to 100 of 259 results

PharmAkea, Celgene and Bay City Capital collaborate on cancer and fibrotic disease

PharmAkea, Celgene and Bay City Capital collaborate on cancer and fibrotic disease


PharmAkea Therapeutics and Bay City Capital have entered a strategic collaboration with Celgene designed…

BiotechnologyCelgeneMergers & AcquisitionsNorth AmericaOncologyPharmAkeaResearch

Cellceutix acquires PolyMedix assets from bankruptcy court


US clinical-stage biopharma firm Cellceutix (OTCBB: CTIX) has acquired substantially all of the assets…

BiotechnologybrilacidinCellceutixMergers & AcquisitionsPharmaceuticalPolyMedixPrurisol

Otsuka confirms takeover bid for Astex Pharmaceuticals for $886 million


Following heavy speculation on Wednesday (see The Pharma Letter story earlier today), this morning Japanese…

Astex PharmaceuticalsBiotechnologyMergers & AcquisitionsOncologyOtsukaPharmaceutical

Otsuka said to be buying Astex Pharma


Japanese mid-size drugmaker Otsuka (TYO: 4768) is planning to acquire USA-based Astex Pharmaceuticals…

Astex PharmaceuticalsBiotechnologyMergers & AcquisitionsOncologyOtsukaPharmaceutical

Sangamo BioSciences to buy Ceregene


In its first takeover bid since 2001, US drugmaker Sangamo BioSciences (Nasdaq: SGMO) has signed a definitive…

BiotechnologyCERE-110CeregeneMergers & AcquisitionsNeurologicalOphthalmicsSangamo BioSciences

Onyx Pharma accepts increased bid from Amgen


Amgen (Nasdaq: AMGN), the world largest independent biotech group, said on Sunday (August 25) that the…

AmgenBayerBiotechnologyKyprolisMergers & AcquisitionsOncologyOnyx PharmaceuticalsPfizer

AstraZeneca nabs Amplimmune for $500 million


In a further bid to expand its ailing research portfolio, Anglo-Swedish drug major AstraZeneca (LSE:…

AmplimmuneAstraZenecaBiotechnologyMergers & AcquisitionsOncologyPharmaceutical

Actelion bid for Ceptaris looks secured as FDA approves Valchlor


Privately-held USA-based Ceptaris Therapeutics revealed yesterday (August 26) that the US Food and Drug…

ActelionBiotechnologyCeptaris TherapeuticsDermatologicalsMergers & AcquisitionsNorth AmericaRegulationValchlor

Chiesi expands rare disease portfolio with acquisition


Privately-owned Italian drugmaker Chiesi Group has signed, through its UK affiliate, a definitive agreement…

BiotechnologyChiesi FarmaceuticiLamazymMergers & AcquisitionsPharmaceuticalRare diseasesZymenex

Endo unit to sell anatomical pathology business


USA-based specialty health care company Endo Health Solutions (Nasdaq: ENDP) says that its wholly owned…

BiotechnologyEndo Health SolutionshealthTronicsMergers & AcquisitionsMetamark Genetics

July a strong month for life sciences IPOs and M&A


The life sciences initial public offering (IPO) market continued to heat up in July as six life sciences…

BiotechnologyCubist PharmaceuticalsFinancialMergers & AcquisitionsPerrigoPharmaceuticalRoche

PharmAthene and Theraclone agree merger


USA-based biodefense company PharmAthene (NYSE MKT: PIP) and privately-held monoclonal antibody specialist…

BiotechnologyMergers & AcquisitionsPharmAtheneTheraclone Sciences

Actelion to reinforce portfolio with acquisition


Through a US subsidiary, Switzerland-based Actelion (SIX: ATLN), Europe's largest biotech firm, has entered…

ActelionBiotechnologyCeptaris TherapeuticsMergers & AcquisitionsValchlor

Health care M&A spending grows in 2nd-qtr 2013, says Irving Levin


Health care merger and acquisition activity strengthened in the second quarter of 2013. (View full video:…

BiotechnologyMergers & AcquisitionsPharmaceutical

Acetylon snags $100 million upfront cash and acquisition option


Privately-held Acetylon and US biotech firm Celgene (Nasdaq: CELG) have entered into an exclusive strategic…

Acetylon PharmaceuticalsBiotechnologyCelgeneLicensingMergers & AcquisitionsNeurologicalOncology

Genesis Biopharma completes merger with Lion Biotech


US biotech firm Genesis Biopharma (OTC Bulletin Board: GNBP) says that it has completed a merger with…

BiotechnologyGenesis BiopharmaLion BiotechnologiesMergers & AcquisitionsOncology

Terms amended in Bellus' acquisition of Thallion


Canada-based drugmaker Bellus Health (TSX: BLU) has amended its agreement to acquire fellow Canadian…

Antibiotics and Infectious diseasesBellus HealthBiotechnologyMergers & AcquisitionsNorth AmericaShigamabsThallion Pharmaceuticals

Spectrum Pharma adds to hematology and oncology portfolio with acquisition


US biotech firm Spectrum Pharmaceuticals (Nasdaq: SPPI) says that it has entered into an agreement to…

BiotechnologyMarqiboMenadioneMergers & AcquisitionsSpectrum PharmaceuticalsTalon Therapeutics

New regenerative company Cesca created through merger


USA-based ThermoGenesis (Nasdaq: KOOL), a leading supplier of enabling technologies for the processing…

BiotechnologyCesca TherapeuticsMergers & AcquisitionsThermoGenesisTotipotentRx

Ocera Thera and Tranzyme complete merger


US clinical-stage biopharma firm Ocera Therapeutics and Tranzyme (Nasdaq: TZYM) have completed their…

BiotechnologyMergers & AcquisitionsNephrology and HepatologyOcera TherapeuticsOCR-002Tranzyme

Italy's Chiesi gains rights to uniQure's Glybera


Netherlands-based venture capital backed human gene therapy firm uniQure has signed collaboration agreements…

BiotechnologyChiesi FarmaceuticiGlyberaLicensingMergers & AcquisitionsPharmaceuticaluniQure

Serodus to acquire Phlogo to expand cardiovascular portfolio


Norwegian biopharma company Serodus (Oslo Axess: SER) says that, following approval by an extraordinary…

BiotechnologyCardio-vascularMergers & AcquisitionsPhlogoSER130SER140Serodus

Nile Therapeutics will merge with Capricor to become new company focused on heart disease


USA-based Nile Therapeutics (OTCQB: NLTX) has today (July 8) announced a merger with privately-held Californian…

BiotechnologyCapricorCapricor TherapeuticscenderitideMergers & AcquisitionsNile Therapeutics

76 to 100 of 259 results

Back to top